{"schema_version":"secwatch.filing_event.v1","accession":"0001728117-23-000133","form_type":"8-K","ticker":"GOSS","cik":"0001728117","company_name":"Gossamer Bio, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.205721+00:00","generated_at":"2026-06-08T07:07:30.187590+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Gossamer Bio Q3 net loss $40M, cash sufficient into H1 2026; PROSERA study ahead","bullets":["Net loss $40.0M ($0.21/share) vs $59.4M loss in Q3 2022; R&D expenses $31.2M (down from $44.5M).","Cash, equivalents & marketable securities $328.9M; expected to fund operations into first half of 2026.","Phase 3 PROSERA site activations ahead of schedule; first patient dosing expected in Q4 2023.","Additional TORREY open-label extension data (seralutinib in PAH) expected in Q4 2023.","FRI sub-study of TORREY presented at ERS 2023; evidence of improved pulmonary blood vessel volume."],"urls":{"canonical":"https://secwatch.observer/filing/0001728117-23-000133","json":"https://secwatch.observer/filing/0001728117-23-000133.json","markdown":"https://secwatch.observer/filing/0001728117-23-000133.md","text":"https://secwatch.observer/filing/0001728117-23-000133.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728117/000172811723000133/0001728117-23-000133-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728117/000172811723000133/goss-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:07:30.187590+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"80c11a69b21e27301f46170c4e63cac8feae0b7e","claim":"Gossamer Bio, Inc. reported third quarter ended September 30, 2023 results: net income $40.0 million, or $0.21 per share, EPS $0.21 per share.","evidence_excerpt":"Net loss for the quarter ended September 30, 2023, was $40.0 million, or $0.21 per share, compared to a net loss of $59.4 million, or $0.65 per share, for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1728117/000172811723000133/0001728117-23-000133-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Net income","value":"$40.0 million, or $0.21 per share"},{"label":"EPS","value":"$0.21 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}